pralsetinib
Gavreto Gets Full Approval for NSCLC With RET Gene Fusions
The FDA granted regular approval to pralsetinib (Gavreto, Genentech) for adult patients with metastatic rearranged ...
AUGUST 10, 2023
Gavreto Approved for Treatment of RET-Altered Thyroid Cancers
The FDA approved pralsetinib (Gavreto, Genentech/Blueprint Medicines) for patients aged 12 years and older with ...
DECEMBER 3, 2020
Load more